Brazilian cancer centers test new biosimilar treatment
NCT ID NCT06808685
Summary
This study is observing how well a biosimilar version of the drug bevacizumab works for people in Brazil with advanced colorectal cancer that has spread and cannot be removed by surgery. Researchers will follow 133 patients who are already receiving this drug as part of their standard first-line treatment. The goal is to collect real-world information on how long the treatment works, its safety, and how it affects survival and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Instituto Dor de Pesquisa E Ensino
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.